Radiopharm Theranostics: Morgan Stanley reports 5.6% stake
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Radiopharm Theranostics Ltd (RADX) is named as the issuer in a beneficial-ownership disclosure by Morgan Stanley and Morgan Stanley Australia Securities Limited; each reported beneficial ownership of 272,558,527 ordinary shares/ADSs, equal to 5.6% of the class, as of September 30, 2026. Both reported shared voting and dispositive power over that amount, with zero sole voting or dispositive power.
Key Figures
Key Terms
beneficially owned regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much RADX did Morgan Stanley report owning?
Does Morgan Stanley's RADX disclosure include every Morgan Stanley unit?
AI-generated analysis. How Rhea-AI works. Not financial advice.